T4827

Sigma-Aldrich

Trandolapril

≥98% (HPLC), white powder

Synonym(s):
(2S,3aR,7aS)-1-(2S)-2-(1S)-1-(Ethoxycarbonyl)-3-phenylpropylamino-1-oxopropyloctahydro-1H-indole-2-carboxylic acid, Mavik
Empirical Formula (Hill Notation):
C24H34N2O5
CAS Number:
Molecular Weight:
430.54
MDL number:
PubChem Substance ID:
NACRES:
NA.77
Pricing and availability is not currently available.

assay

≥98% (HPLC)

form

white powder

solubility

DMSO: ≥20 mg/mL

originator

Abbott

SMILES string

CCOC(=O)C@H(CCc1ccccc1)NC@@H(C)C(=O)N2C3CCCCC3CC@H2C(O)=O

InChI

1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

InChI key

VXFJYXUZANRPDJ-WTNASJBWSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Application

Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).

Packaging

10, 50 mg in glass bottle

Biochem/physiol Actions

Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. T4827.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Precautionary Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
V B Simonenko et al.
Klinicheskaia meditsina, 89(2), 29-31 (2011-05-18)
The study was designed to evaluate effect of trandolapril, an ACE inhibitor, on platelet aggregation in patients with arterial hypertension and impaired glucose tolerance. The drug was given to 38 patients for 12 weeks. The key end points were dynamics...
Christian Lewinter et al.
European journal of heart failure, 13(12), 1349-1354 (2011-10-27)
Patients with acute myocardial infarction (MI) with bundle branch block (BBB) have a poor prognosis, but distinction between left (L)- and right (R)-sided BBB is seldom made in epidemiological studies. We studied long-term mortality associated with RBBB and LBBB in...
Anthony A Bavry et al.
The American journal of medicine, 124(7), 614-620 (2011-05-21)
There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensive patients with coronary artery disease. This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary...
M Dendeni et al.
International journal of pharmaceutics, 438(1-2), 61-70 (2012-09-11)
Various regulatory authorities like International Conference on Harmonization (ICH), US Food and Drug Administration, Canadian Drug and Health Agency are emphasizing on the purity requirements and the identification of impurities in active pharmaceutical drugs. Qualification of the impurities is the...
Michelle L O'Donoghue et al.
Clinical chemistry, 57(9), 1311-1317 (2011-07-26)
Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD). We measured plasma sPLA(2) activity at baseline in 3708 subjects in the PEACE...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.